An observational study in Contraception, sponsored by Femasys Inc.. Active, not recruiting at 20 sites in Spain. Open to female participants aged 21 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Femasys Inc. · Observational
A Prospective Observational Pilot Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive Method in Spain
A Prospective Observational Pilot Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive Method in Spain
Femasys Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Females of child-bearing age who desire permanent birth control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device
Device: FemBloc Permanent Birth Control
Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
Degree of patient satisfaction
To evaluate the acceptance of the FemBloc procedure in real life by female candidates by measuring the degree of satisfaction reported by participants on Likert scale (1-5, 5=highest satisfaction)
Time frame: At time of procedure
Evaluation of device- and/or procedure-related safety events
Number of participants with device- and/or procedure-related adverse events
Time frame: At the time of procedure and up through 3 months post procedure
Pain
Measure the degree of pain reported by participants on Visual Analog Scale (0-10 scale, 10 = intense pain)
Time frame: At the time of procedure
Bilateral occlusion rate
Rate of bilateral tubal occlusion using saline-air contrast ultrasound
Time frame: 3 months post procedure
Pregnancy rate
Rate of pregnancies among the participants
Time frame: 12 months post procedure and confirmation test
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Femasys Inc.